ROCHE HOLDING AG-BR will acquire PathAI for $750 million upfront and up to $300 million in milestone payments. The deal follows a five-year partnership between Roche and PathAI that expanded in 2024. This acquisition integrates AI-enabled companion diagnostics into Roche's core pathology division to improve cancer treatment precision.

Automating the Pathology Workflow